Literature DB >> 4204490

Immunogenicity of purified, inactivated chikungunya virus in monkeys.

E Nakao, S Hotta.   

Abstract

Chikungunya (CHIK) virus, harvested from infected BHK-21 cell cultures and highly purified by a method combining zinc acetate precipitation, Sephadex-Sepharose column chromatography, and sucrose density gradient centrifugation, was subjected to ultraviolet (UV) irradiation and treatment with formalin. Inactivation of the virus by UV light was apparently a first-order reaction. The virus treated with 0.05% formalin at 4 degrees C was inactivated completely after 7 weeks, but when treated with 0.025% formalin retained its plaque infectivity at least 17 weeks. Both UV- and formalin-inactivated viruses induced production of anti-CHIK neutralizing antibodies in Japanese monkeys with no preimmune antibodies. Judging by the titres of antibodies produced, the immunogenic effect of the UV-irradiated virus was superior to that of the formalin-treated virus.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4204490      PMCID: PMC2482923     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  Plaque assay of dengue and other group B arthropod-borne viruses under methyl cellulose overlay media.

Authors:  I T SCHULZE; R W SCHLESINGER
Journal:  Virology       Date:  1963-01       Impact factor: 3.616

2.  Use of methyl cellulose gel as a substitute for agar in tissue-culture overlays.

Authors:  J E HOTCHIN
Journal:  Nature       Date:  1955-02-19       Impact factor: 49.962

3.  Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence.

Authors:  I MACPHERSON; M STOKER
Journal:  Virology       Date:  1962-02       Impact factor: 3.616

4.  Biolgoical and immunological studies on chikungunya virus: a comparative observation of two strains of African and Asian origins.

Authors:  E Nakao
Journal:  Kobe J Med Sci       Date:  1972-06

5.  Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues.

Authors:  V R Harrison; L N Binn; R Randall
Journal:  Am J Trop Med Hyg       Date:  1967-11       Impact factor: 2.345

6.  Immunological properties of Chikungunya virus and its components.

Authors:  A Igarashi; P Nithiuthai; S Rojanasuphot
Journal:  Biken J       Date:  1970-09

7.  Purification of arboviruses grown in tissue culture.

Authors:  Y Yoshinaka; S Hotta
Journal:  Proc Soc Exp Biol Med       Date:  1971-07

8.  Production and evaluation of a formalin-killed Chikungunya vaccine.

Authors:  V R Harrison; K H Eckels; P J Bartelloni; C Hampton
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

9.  Chikungunya virus vaccine prepared by Tween-ether extraction.

Authors:  K H Eckels; V R Harrison; F M Hetrick
Journal:  Appl Microbiol       Date:  1970-02

10.  Immunogenicity of purified venezuelan equine encephalitis virus inactivated by ionizing radiation.

Authors:  J Gruber
Journal:  Infect Immun       Date:  1971-04       Impact factor: 3.441

View more
  15 in total

1.  Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.

Authors:  Adam D DeZure; Nina M Berkowitz; Barney S Graham; Julie E Ledgerwood
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

Review 2.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

3.  A chikungunya fever vaccine utilizing an insect-specific virus platform.

Authors:  Jesse H Erasmus; Albert J Auguste; Jason T Kaelber; Huanle Luo; Shannan L Rossi; Karla Fenton; Grace Leal; Dal Y Kim; Wah Chiu; Tian Wang; Ilya Frolov; Farooq Nasar; Scott C Weaver
Journal:  Nat Med       Date:  2016-12-19       Impact factor: 53.440

4.  A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis.

Authors:  Danher Wang; Andreas Suhrbier; Adam Penn-Nicholson; Jan Woraratanadharm; Joy Gardner; Min Luo; Thuy T Le; Itaru Anraku; Michael Sakalian; David Einfeld; John Y Dong
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

Review 5.  Arthritogenic alphaviruses--an overview.

Authors:  Andreas Suhrbier; Marie-Christine Jaffar-Bandjee; Philippe Gasque
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

6.  Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library.

Authors:  Deu John M Cruz; Rafaela M Bonotto; Rafael G B Gomes; Camila T da Silva; Juliana B Taniguchi; Joo Hwan No; Benoit Lombardot; Olivier Schwartz; Michael A E Hansen; Lucio H Freitas-Junior
Journal:  PLoS Negl Trop Dis       Date:  2013-10-31

Review 7.  Antiviral perspectives for chikungunya virus.

Authors:  Deepti Parashar; Sarah Cherian
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

8.  Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.

Authors:  Petra van den Doel; Asisa Volz; Jouke M Roose; Varsha D Sewbalaksing; Gorben P Pijlman; Ingeborg van Middelkoop; Vincent Duiverman; Eva van de Wetering; Gerd Sutter; Albert D M E Osterhaus; Byron E E Martina
Journal:  PLoS Negl Trop Dis       Date:  2014-09-04

Review 9.  Chikungunya Virus Vaccines: Platforms, Progress, and Challenges.

Authors:  Victor R DeFilippis
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.291

Review 10.  Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model).

Authors:  Rebecca Broeckel; Nicole Haese; Ilhem Messaoudi; Daniel N Streblow
Journal:  Pathogens       Date:  2015-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.